CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy.

TitleCD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy.
Publication TypeJournal Article
Year of Publication2013
AuthorsTaiwo B, Hunt PW, Gandhi RT, Ellingson A, McKenna M, Jacobson JM, Gripshover B, Bosch RJ
JournalJ Acquir Immune Defic Syndr
Volume63
Issue1
Pagination101-4
Date Published2013 May 1
ISSN1944-7884
KeywordsAdult, Antigens, CD38, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Female, HIV Infections, HIV-1, HLA-DR Antigens, Humans, Lymphocyte Activation, Male, Membrane Glycoproteins, RNA, Viral, Treatment Outcome, Viremia
Abstract

Transient low-level viremia (TLLV) of 50-400 HIV RNA copies per milliliter is common during antiretroviral therapy, but its pathogenesis, consequences, and optimal management are unclear. Heightened immune activation is associated with detrimental outcomes, including impaired CD4 T-cell reconstitution. Using CD38/HLA-DR expression on CD8 T cells measured in 2 large studies, we determined associations between TLLV and immune activation levels before, during, and after TLLV. We found that TLLV does not significantly change CD8 T-cell activation and that higher CD8 T-cell activation during viral suppression <50 copies per milliliter is associated with a modest increase in the risk of a subsequent TLLV.

DOI10.1097/QAI.0b013e3182895af4
Alternate JournalJ. Acquir. Immune Defic. Syndr.
PubMed ID23392463
PubMed Central IDPMC3632289
Grant ListU01 AI068634 / AI / NIAID NIH HHS / United States
U01 AI068636 / AI / NIAID NIH HHS / United States
U01AI068636 / AI / NIAID NIH HHS / United States
U01AI68634 / AI / NIAID NIH HHS / United States
UM1 AI069412 / AI / NIAID NIH HHS / United States
UM1 AI069471 / AI / NIAID NIH HHS / United States
UM1 AI069496 / AI / NIAID NIH HHS / United States